Bhatti Najeeha Ahmad, Jobilal Anna, Asif Kainat, Jaramillo Villegas Mateo, Pandey Priyanka, Tahir Ayzal Noor, Balla Neeharika, Arellano Camargo Maryoreht Paola, Ahmad Sana, Kataria Janvi, Abdin Zain U, Ayyan Muhammad
Internal Medicine, Noonu Atoll Hospital, Manadhoo, MDV.
Internal Medicine, Sri Ramaswamy Memorial Medical College Hospital and Research Centre, Kattankulathur, IND.
Cureus. 2023 Aug 24;15(8):e44038. doi: 10.7759/cureus.44038. eCollection 2023 Aug.
Depressive disorders are caused due to the impaired functioning of important brain networks. Recent studies have also shown that it is caused by a significant reduction in the levels of allopregnanolone, which is a progesterone metabolite. Newer treatment modalities are now focusing on the usage of neuroactive steroids, such as allopregnanolone, in various depressive disorders. Our aim was to provide a comprehensive literature review on the clinical aspects of the allopregnanolone agonists brexanolone and zuranolone with reference to the physiological role of allopregnanolone. Brexanolone was approved by the FDA in 2019 for the treatment of postpartum depression and has greatly influenced further research into potential drugs such as zuranolone, which is currently undergoing phase 3 of clinical trials. Although these drugs exhibit improvement in symptoms of depressive disorders along with notable side effects, further research is required for their future clinical use.
抑郁症是由重要脑网络功能受损所致。近期研究还表明，它是由孕烷醇酮（一种孕酮代谢物）水平显著降低引起的。新型治疗方式目前正聚焦于使用神经活性甾体，如孕烷醇酮，来治疗各种抑郁症。我们的目的是结合孕烷醇酮的生理作用，对孕烷醇酮激动剂布瑞诺龙和祖拉诺龙的临床方面进行全面的文献综述。布瑞诺龙于2019年获美国食品药品监督管理局批准用于治疗产后抑郁症，并极大地影响了对祖拉诺龙等潜在药物的进一步研究，祖拉诺龙目前正处于临床试验的3期阶段。尽管这些药物在改善抑郁症症状的同时伴有明显副作用，但它们未来的临床应用仍需进一步研究。
